(Q38127449)

29 August 2017

Finding chemo: the search for marine-based pharmaceutical drugs active against cancer (English)

1 reference

29 August 2017

Sivanjah Indumathy

1

1 reference

PubMed ID

23927467

29 August 2017

Crispin R Dass

series ordinal

2

1 reference

PubMed ID

23927467

29 August 2017

language of work or name

1 reference

10 July 2013

1 reference

Journal of Pharmacy and Pharmacology

29 August 2017

1 reference

29 August 2017

65

1 reference

29 August 2017

9

1 reference

29 August 2017

1280-1301

1 reference

29 August 2017

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Targeting the hallmarks of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Cell death pathology: the war against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Triggering caspase-independent cell death to combat cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

A review of trabectedin (ET-743): a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Kinases as targets in the treatment of solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Signal transduction by the JNK group of MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Regulation of phosphoinositide 3-kinase expression in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Akt enhances Mdm2-mediated ubiquitination and degradation of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Protein kinase C epsilon: an oncogene and emerging tumor biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Protein kinase Cepsilon makes the life and death decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Targeting cellular proapoptotic molecules for developing anticancer agents from marine sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

BH3-only proteins and their roles in programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Role of Bcl-2 family proteins and caspases in the regulation of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Clinical status of anti-cancer agents derived from marine sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Porifera and Coelenterata

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Anticancer drugs designed by mother nature: ancient drugs but modern targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Bio-mining the microbial treasures of the ocean: new natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Bryozoa, Mollusca, Echinodermata and Urochordata

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Cancer, chitosan nanoparticles and catalytic nucleic acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Caspase 2 activation and ER stress drive rapid Jurkat cell apoptosis by clofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Cell cycle kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Cryptosphaerolide, a cytotoxic Mcl-1 inhibitor from a marine-derived ascomycete related to the genus Cryptosphaeria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Halocynthiaxanthin and fucoxanthinol isolated from Halocynthia roretzi induce apoptosis in human leukemia, breast and colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Ircinin-1 induces cell cycle arrest and apoptosis in SK-MEL-2 human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Inhibition of protein synthesis and activation of stress-activated protein kinases by onnamide A and theopederin B, antitumor marine natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Porphyran induces apoptosis related signal pathway in AGS gastric cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Pachastrissamine from Pachastrissa sp. inhibits melanoma cell growth by dual inhibition of Cdk2 and ERK-mediated FOXO3 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Pachastrissamine (jaspine B) and its stereoisomers inhibit sphingosine kinases and atypical protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Induction of apoptosis by phloroglucinol derivative from Ecklonia Cava in MCF-7 human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Differential effects of triterpene glycosides, frondoside A and cucumarioside A2-2 isolated from sea cucumbers on caspase activation and apoptosis of human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

The marine sponge toxin agelasine B increases the intracellular Ca(2+) concentration and induces apoptosis in human breast cancer cells (MCF-7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

From the sea to anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Cytarabine dose for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Neuroprotective properties of chitosan and its derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Cell death independent of caspases: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Caspase-independent pathways of programmed cell death: the unraveling of new targets of cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Mitochondrial control of caspase-dependent and -independent cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Regulation and interplay of apoptotic and non-apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

Role of Smac in cephalostatin-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12097

21 January 2018

Identifiers

DOI

10.1111/JPHP.12097

1 reference

29 August 2017

1 reference

PubMed ID

23927467